التفاصيل البيبلوغرافية
| العنوان: |
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. |
| المؤلفون: |
Bertacchini, J, Guida, M, Accordi, B, Mediani, L, Martelli, A M, Barozzi, P, Petricoin, E, Liotta, L, Milani, G, Giordan, M, Luppi, M, Forghieri, F, De Pol, A, Cocco, L, Basso, G, Marmiroli, S |
| المصدر: |
Leukemia (08876924); Nov2014, Vol. 28 Issue 11, p2197-2205, 9p, 2 Charts, 6 Graphs |
| مصطلحات موضوعية: |
HEMATOLOGIC malignancies, ACUTE myeloid leukemia, PROTEOMICS, PROTEIN microarrays, PHOSPHATIDYLINOSITOLS, PHOSPHOLIPIDS, GROWTH factors |
| مستخلص: |
Acute myeloid leukemia (AML) primary cells express high levels of phosphorylated Akt, a master regulator of cellular functions regarded as a promising drug target. By means of reverse phase protein arrays, we examined the response of 80 samples of primary cells from AML patients to selective inhibitors of the phosphatidylinositol 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) axis. We confirm that >60% of the samples analyzed are characterized by high pathway phosphorylation. Unexpectedly, however, we show here that targeting Akt and mTOR with the specific inhibitors Akti 1/2 and Torin1, alone or in combination, result in paradoxical Akt phosphorylation and activation of downstream signaling in 70% of the samples. Indeed, we demonstrate that cropping Akt or mTOR activity can stabilize the Akt/mTOR downstream effectors Forkhead box O and insulin receptor substrate-1, which in turn potentiate signaling through upregulation of the expression/phosphorylation of selected growth factor receptor tyrosine kinases (RTKs). Activation of RTKs in turn reactivates PI3K and downstream signaling, thus overruling the action of the drugs. We finally demonstrate that dual inhibition of Akt and RTKs displays strong synergistic cytotoxic effects in AML cells and downmodulates Akt signaling to a much greater extent than either drug alone, and should therefore be explored in AML clinical setting. [ABSTRACT FROM AUTHOR] |
|
Copyright of Leukemia (08876924) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder